Furthermore, future studies should include determining the sensitivities of the aPTT and PT to coagulation factor deficiencies and to direct oral factor IIa or factor Xa inhibitors (e.g. dabigatran, rivaroxaban and apixaban). The gene discussed is F10; the disease is complement factor I deficiency.